全文获取类型
收费全文 | 251篇 |
免费 | 17篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 4篇 |
临床医学 | 22篇 |
内科学 | 23篇 |
皮肤病学 | 14篇 |
特种医学 | 3篇 |
外科学 | 3篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 19篇 |
肿瘤学 | 177篇 |
出版年
2024年 | 1篇 |
2022年 | 3篇 |
2021年 | 8篇 |
2020年 | 9篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 7篇 |
2016年 | 5篇 |
2015年 | 24篇 |
2014年 | 26篇 |
2013年 | 23篇 |
2012年 | 27篇 |
2011年 | 22篇 |
2010年 | 16篇 |
2009年 | 4篇 |
2008年 | 11篇 |
2007年 | 15篇 |
2006年 | 8篇 |
2005年 | 8篇 |
2004年 | 10篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有268条查询结果,搜索用时 15 毫秒
1.
Razelle Kurzrock 《Clinical cancer research》2005,11(4):1361-1367
Thrombocytopenia is a serious clinical problem in several different clinical settings. In chronic bone marrow failure states, which include aplastic anemia, myelodysplastic syndrome, and graft failure, the prolonged nature of thrombocytopenia often leads to alloimunization after repeated platelet transfusions, the consequence of which is a platelet-refractory state and enhanced risk of bleeding. Despite the introduction of several thrombopoietic factors into clinical trials, an effective way to alleviate thrombocytopenia has been elusive, and the problem in chronic bone marrow failure states has remained poorly addressed by clinical investigations. Even so, several studies by our group and others suggest that a subset of patients suffering from chronic bone marrow failure can respond to appropriate growth factor therapy. The temporal pace of response appears, however, to be much slower than that observed after administering growth factors which act on neutrophils. On the other hand, durable responses can be secured in some patients given thrombopoietic factors for long periods of time. Herein, we provide an overview of the clinical research investigations of thrombopoietic factors in chronic bone marrow failure, and the emerging insights these studies provide for understanding the process of thrombopoiesis and its therapy in this setting. 相似文献
2.
3.
Falchook GS Long GV Kurzrock R Kim KB Arkenau TH Brown MP Hamid O Infante JR Millward M Pavlick AC O'Day SJ Blackman SC Curtis CM Lebowitz P Ma B Ouellet D Kefford RF 《Lancet》2012,379(9829):1893-1901
4.
5.
6.
Anthony W. Tolcher Razelle Kurzrock Vincente Valero Rene Gonzalez Rebecca S. Heist Antoinette R. Tan Julie Means-Powell Theresa L. Werner Carlos Becerra Chenxi Wang Cathrine Leonowens Shanker Kalyana-Sundaram Joseph F. Kleha Jennifer Gauvin Anthony M. DAmelio Catherine Ellis Nageatte Ibrahim Li Yan 《Cancer chemotherapy and pharmacology》2020,85(4):673-683
This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and/or AKT inhibition. This was a phase I, open-label, dose-escalation, and dose-expansion study in patients with triple-negative breast cancer or BRAF-wild type advanced melanoma. The primary outcome of the expansion study was investigator-assessed response. Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts. Doses tested in the expansion cohort were trametinib 1.5 mg once daily (QD) + uprosertib 50 mg QD. Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity. Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate. Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively. Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity. The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing. The objective response rate was < 5% (1 complete response, 5 partial responses). Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested. 相似文献
7.
8.
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies 总被引:3,自引:0,他引:3
BACKGROUND: Interferon-alpha (IFN-alpha) and retinoids have shown nonoverlapping toxicity and each has shown antitumor activity in patients with lymphoma. The aim of the current study was to assess the toxicity, safety, and efficacy of IFN-alpha combined with isotretinoin in patients with advanced, refractory lymphoid malignancies. METHODS: Adults with biopsy-proven advanced lymphoid malignancy were treated. Patients with compromised bone marrow function (platelet counts as low as 30 x 10(9)/L) were eligible. Treatment was comprised of IFN-alpha at a starting daily dose of 3 mega units subcutaneously and isotretinoin orally starting at a dose of 1 mg/kg daily in 2 divided doses. RESULTS: Forty-four patients were evaluable. Their median age was 57 years (range, 18-82 years). Eighteen patients had advanced cutaneous T-cell lymphoma, 6 patients had peripheral T-cell lymphoma, 14 patients had Hodgkin disease, and 6 patients had a variety of other lymphoid malignancies. Patients with Hodgkin disease had received a median of 6 previous therapies (range, 3-12 therapies) and patients with other lymphoid malignancies had received a median of 4 previous therapies (range, 1-9 therapies). The median duration of treatment was 4 months (range, 0.25-38 months). The overall response rate was 38.6% (complete response in 5 patients [11.3%] and partial response in 12 patients [27.3%]). The median response duration was 3 months (range, 1-95+ months). The most common toxicities were low-grade fever, flu-like symptoms, and fatigue (IFN-alpha effects); dry mouth and skin and hypertriglyceridemia (cis-retinoic acid effects); and thrombocytopenia (which generally occurred in patients with low baseline platelet counts). CONCLUSIONS: IFN-alpha and isotretinoin combination therapy had antitumor activity and was well tolerated in heavily pretreated patients with lymphoid malignancies. 相似文献
9.
10.